EQT Fund Management S.a r.l.

Portfolio Overview

EQT Fund Management S.a r.l. disclosed 5 positions worth $1.0B in its Form 13F-HR for Q1 2026, led by $WAY (Waystar Holding Corp.) at 58.8% of the equity portfolio, followed by $OCS and $EVMN. During the quarter the fund opened 1 new position and exited 0 — including a new stake in $AGMB. The portfolio is most concentrated in Technology (58.8% of disclosed assets). All figures are sourced directly from EQT Fund Management S.a r.l.’s Form 13F-HR filing with the SEC under CIK 1834239.

• 

  Waystar Holding Corp.

  $WAY

  71.4#264

  Quality

  $599.8M24,879,437 sh
• 

  Oculis Holding AG

  $OCS

  —

  Quality

  $156.9M5,900,294 sh
• 

  Evommune, Inc.

  $EVMN

  —

  Quality

  $113.3M4,929,633 sh
• 

  Pharvaris N.V.

  $PHVS

  —

  Quality

  $96.7M3,424,609 sh
• 

  Agomab Therapeutics NV

  $AGMB

  —

  Quality

  $53.9M5,141,992 sh

Company	Quality	Value	Shares
Waystar Holding Corp.$WAY	71.4#264	$599.8M	24,879,437
Oculis Holding AG$OCS	—	$156.9M	5,900,294
Evommune, Inc.$EVMN	—	$113.3M	4,929,633
Pharvaris N.V.$PHVS	—	$96.7M	3,424,609
Agomab Therapeutics NV$AGMB	—	$53.9M	5,141,992

Showing top 5 of 5 holdings.

Full Holdings — EQT Fund Management S.a r.l. (Q1 2026)

All 5 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.

#	Ticker	Company	Value	Weight	QoQ	Quality
1	$WAY	Waystar Holding Corp.	$599.8M	58.8%	+0%	71.4
2	$OCS	Oculis Holding AG	$156.9M	15.4%	+0%	—
3	$EVMN	Evommune, Inc.	$113.3M	11.1%	+0%	—
4	$PHVS	Pharvaris N.V.	$96.7M	9.5%	+0%	—
5	$AGMB	Agomab Therapeutics NV	$53.9M	5.3%	NEW	—